To the Editor:

Sudden cardiac death in a young athlete is a tragic event, and emerging data suggest that the leading finding associated with sudden cardiac death in athletes is autopsy-negative sudden unexplained death \[[@C1]\]. Sleep disordered breathing (SDB) can be arrhythmogenic and lead to sudden cardiac death \[[@C2], [@C3]\]. While obstructive sleep apnoea is generally prevalent in obese, inactive and/or aged subjects \[[@C4]\], little is known about its incidence in young athletes and highly active young people. Consequently, the impact of SDB on cardiovascular health of young athletes has not been fully elucidated. Athletes who participate in collision sports such as rugby and American football tend to exhibit risk factors for SDB such as large neck circumference and higher body mass index \[[@C5]\]. In this context, we investigated the prevalence and significance of SDB in young competitive athletes with a view to advancing the research conducted on athlete health.

47 male freshman athletes on a rugby football team at the Nippon Sport Science University underwent comprehensive cardiorespiratory evaluations in 2015 and 2016. The institutional review board of Showa University Fujigaoka Rehabilitation Hospital approved the protocol. Written informed consent was obtained from all subjects. This study was performed on 42 of the athletes (mean±[sd]{.smallcaps} 18.6±0.5 years old, experience 8.2±4.0 years) who completed SDB evaluations using a WatchPAT-200 device (Itamar Medical Ltd., Caesarea, Israel), a validated surrogate for polysomnography \[[@C6]\]. 18 (43%) of the subjects evaluated met the definition set for SDB: an apnoea--hypopnoea index (AHI) of ≥5 events·h^−1^ over a total sleeping time of more than 3 h. This SDB prevalence exceeded that previously reported in middle-aged men in the US and European general population \[[@C4], [@C7]\]. The severity of the SDB was mild (5≤AHI\<15 events·h^−1^) in 16 of the athletes and moderate (15≤AHI\<30 events·h^−1^) in two athletes. None of the athletes exhibited severe SBD (AHI: ≥30 events·h^−1^).

Bioelectrical impedance analysis was performed to determine body composition, and neck circumference was manually measured. In the comparison between the athletes with and without SDB, there were no significant differences in the field-position, body composition, neck circumference or Epworth Sleepiness Scale ([table 1](#TB1){ref-type="table"}). According to the analyses of the WatchPAT data collected during sleep, AHI showed a significant inverse correlation with the minimum oxygen saturation (r= −0.696, p\<0.0001) and significant positive correlations with the oxygen desaturation index (r=0.889, p\<0.0001) and average heart rate (r=0.426, p\<0.01). Hence, the sleeping SDB athletes exhibited a significantly lower minimum oxygen saturation, and significantly higher oxygen desaturation index and average heart rate, compared with the sleeping athletes without SDB ([table 1](#TB1){ref-type="table"}).

###### 

Demographics and cardiopulmonary evaluation of athletes with and without sleep disordered breathing (SDB)

                                            **All**     **Non-SDB**    **SDB**     **p-value**
  --------------------------------------- ------------ ------------- ------------ -------------
  **Position played forwards:backs**         18:24         8:16          10:8         0.15
  **Height cm**                            174.2±6.5     173.8±5.9    174.7±7.3       0.67
  **Weight kg**                            84.1±13.8     84.0±11.8    84.1±16.5       0.99
  **Body mass index kg·m^−2^**              27.7±4.0     27.8±3.2      27.5±5.0       0.85
  **BSA m^2^**                              2.0±0.2       2.0±0.2      2.0±0.2        0.99
  **Neck circumference cm**                 42.1±2.5     42.2±1.8      42.0±3.2       0.73
  **Muscle weight, trunk kg**               29.3±3.5     29.3±3.4      29.3±3.8       0.98
  **Muscle weight, limb kg**                28.6±4.1     28.8±3.8      28.3±4.6       0.70
  **% Body fat**                            20.3±7.9     20.9±7.6      19.5±8.4       0.59
  **Epworth sleepiness scale**              9.0±4.0       8.3±3.3      9.9±4.7        0.19
  **WatchPAT data**                                                               
   AHI                                      5.4±4.4       2.5±1.3      9.4±3.9      \<0.0001
   ODI                                      2.1±2.2       0.9±0.8      3.6±2.5      \<0.0001
   Mean oxygen saturation %                 96.5±0.6     96.6±0.7      96.4±0.5       0.37
   Minimum oxygen saturation %              90.8±3.6     91.9±2.6      89.2±4.2       0.02
   Mean heart rate beats·min^−1^            54.3±5.2     52.4±5.5      56.7±3.6      \<0.01
  **Echocardiography**                                                            
   LVEF %                                   65.5±4.7     66.0±4.7      64.9±4.9       0.50
   LVEDV mL                                152.2±26.1   151.9±27.7    152.6±24.7      0.93
   LVEDV/BSA                               75.2±10.3     75.1±10.7    75.3±10.2       0.96
   LVESV mL                                53.6±10.6     52.1±9.9     55.5±11.4       0.30
   LVESV/BSA                                26.6±5.0     25.8±4.3      27.5±5.8       0.29
   Stroke volume mL                        98.8±19.5    100.1±21.6    97.2±17.0       0.65
   Stroke volume/BSA                        48.7±7.7     49.4±8.7      47.8±6.3       0.52
   LVDd mm                                  52.8±3.1     53.1±2.6      52.4±3.8       0.48
   LVDd/BSA                                 26.1±1.9     26.3±1.6      26.0±2.2       0.61
   IVS mm                                   10.0±0.8      9.9±0.8      10.2±0.9       0.28
   PWT mm                                   9.8±0.8       9.8±0.7      9.9±0.8        0.64
   LVM g                                   197.9±30.4   197.7±25.4    198.1±36.9      0.96
   LVMI                                    98.1±13.5     98.4±12.9    97.7±14.7       0.88
   LAD mm                                   36.2±4.0     36.6±4.3      35.6±3.6       0.40
   LAVI                                     29.9±6.0     30.6±6.3      28.8±5.6       0.35
    Right atrial area mm^2^                 19.2±3.1     19.4±3.2      18.9±3.0       0.61
    Aortic diameter mm                      30.5±2.3     30.4±2.4      30.6±2.1       0.80
   E/e′                                     6.4±1.4       6.3±1.6      6.6±1.0        0.48
  **CPET**                                                                        
   Rest heart rate beats·min^−1^            72.5±7.4     70.4±7.2      75.0±7.0       0.05
   Peak heart rate beats·min^−1^           164.9±16.7   162.4±17.1    167.8±16.1      0.32
   Rest SBP mmHg                           127.3±17.0   128.5±17.7    125.8±16.4      0.63
   Peak SBP mmHg                           199.7±23.0   196.2±20.6    203.8±25.4      0.31
   RMR mL·min^−1^·kg^−1^                    4.1±0.6       4.3±0.5      4.0±0.6        0.20
   Peak oxygen uptake mL·min^−1^·kg^−1^     36.9±6.9     36.6±6.3      37.2±7.7       0.81
  **24-h Holter ECG**^\#^                                                         
   Mean heart rate beats·min^−1^            67.4±5.8     66.3±5.5      68.5±6.1       0.24
   Maximum heart rate beats·min^−1^        135.3±13.8   136.7±16.4    133.2±9.0       0.43
   Minimum heart rate beats·min^−1^         36.1±4.2     36.3±3.9      35.8±4.7       0.71
   PVCs on Holter                                                                 
   Counts n (%)                                                                       0.02
    0                                      21 (51.2%)    12 (50%)     9 (52.9%)   
    1--99                                  16 (39.0%)    12 (50%)     4 (23.5%)   
    ≥100                                    4 (9.8%)      0 (0%)      4 (23.5%)   
   Run n (%)                                                                          1.00
    2 run                                   2 (4.9%)     1 (4.2%)      1 (5.9%)   
    3--4 run                                1 (2.4%)     1 (4.2%)       0 (0%)    

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. Total subjects=42, 24 in the non-SDB group and 18 in the SDB. BSA: body surface area; AHI: apnoea--hypopnoea index; ODI: oxygen desaturation index; LV: left ventricle; EF: ejection fraction; EDV: end-diastolic volume; ESV: end-systolic volume; Dd: end-diastolic diameter; LVM: left ventricular mass; LVMI: left ventricular mass index; IVS: end-diastolic interventricular septum thickness; PWT: end-diastolic posterior wall thickness; LAD: left atrial diameter; LAVI: left atrial volume index; E wave: early diastolic filling velocity: e′: early diastolic velocity; CPET: cardiopulmonary exercise testing; SBP: systolic blood pressure; RMR: resting metabolic rate; PVC: premature ventricular complex. ^\#^: number of SDB athletes was 17 because one athlete in the SDB group had a recording error.

Echocardiography, cardiopulmonary exercise testing (CPET) \[[@C8]\], 24-h Holter monitoring and ophthalmologic examinations were performed to evaluate cardiovascular abnormalities. No congenital heart or valvular diseases or apparent cardiomyopathies were detected in the echocardiography, although adaptive cardiac changes were found. The rugby football athletes exhibited greater mean values for the following parameters compared with previously reported reference values for Japanese males in their twenties \[[@C9]\]: left ventricular end-diastolic volume per body surface area (BSA), left ventricular mass per BSA, left atrial volume index and right atrial area. The parameters for systolic and diastolic function, by contrast, were normal in the athletes. There were no differences in the echocardiographic parameters between the SDB athletes and non-SDB athletes ([table 1](#TB1){ref-type="table"}). The resting heart rate at the beginning of the CPET examination was higher in the SDB athletes than in the non-SDB athletes. There were no differences between the two groups in the systolic blood pressure at rest and at maximal exercise. Likewise, there were no significant differences between them in terms of peak oxygen consumption evaluated by respiratory gas analysis. The prevalence of subjects with premature ventricular complex (PVC) counts \>100 per 24 h in ambulatory Holter recording was significantly greater in the SDB group than in the non-SDB group (23.5% *versus* 0%, p\<0.05). According to reports from the team physicians none of the athletes suffered significant or fatal cardiac events during the 1-year follow-up.

Funduscopy and intraocular pressure measurements were performed by ophthalmologists who had no knowledge of the data from the cardiovascular evaluations. No microvascular damage or atherosclerotic changes in the retina were detected in the SDB athletes or non-SDB athletes, and no difference in intraocular pressure was observed between the two groups (mean±[sd]{.smallcaps} 13.0±0.5 mmHg in the SDB athletes *versus* 14.2±0.5 mmHg in the non-SDB athletes). The ophthalmologic examinations were repeated when the athletes became sophomores. None of the SDB or non-SDB athletes showed microvascular damage or atherosclerotic changes of the retina in this second round of examinations. However, the changes in intraocular pressure were slightly, but significantly, higher in the SDB athletes than in the non-SDB athletes (1.04±0.14 in the SDB *versus* 0.93±0.14 in the non-SDB), although the pressures in the SDB athletes remained within normal range.

The subjects were given a questionnaire to identify incidences of concussion and sports-related injuries in the 1-year follow-up performed when the freshman became sophomores. No difference in the incidence of concussion was found between the two groups (27.8% in the SDB athletes *versus* 34.8% in the non-SDB athletes), whereas the SDB group had a three-fold higher prevalence of athletes who underwent orthopaedic surgery for sports-related trauma or dropped out of the sport because of severe injury compared with the non-SDB group (28.8% *versus* 8.7%). This difference in prevalence did not reach statistical significance. SDB affects neurocognitive function in children \[[@C10]\]. We thus surmise that poor attention in the SDB athletes could cause, at least in part, serious sport-related injury.

The results of the present study demonstrated that the heart rate in sleep, PVC counts in the Holter monitoring, and change ratio of the intraocular pressure were significantly higher in the teenage rugby players with SDB than in the non-SDB athletes. While no serious pathological conditions had yet developed in the young SDB athletes, SDB, even in the mild stage, is known to disturb the balance between the sympathetic and parasympathetic nerve activity in ways that potentially lead to adverse cardiovascular complications \[[@C11], [@C12]\]. The Wisconsin Cohort Study \[[@C13]\] found a significantly increased risk of combined coronary heart disease and heart failure in patients with mild SDB compared with the non-SDB group. SDB has also been shown to be associated with ophthalmic diseases including retinal vascular disease and glaucoma \[[@C14]\]. Thus, the present results would underscore the importance of SDB screening in young collision athletes, although further studies will be necessary to explore the mechanisms underlying onset of SDB in such athletes.

The limitations of this study were noteworthy. SDB assessment was performed on a single night, which may have introduced additional variability \[[@C15]\], even though it remains a standard. Also, the small number of subjects and the additional stratification of the study cohort by AHI limited the power of the study and introduced the possibility of type II error.

In conclusion, SDB was more prevalent in the adolescent rugby football athletes than expected, and several potential warning signs related to autonomic nerve activity appeared in the SDB athletes. SDB screening may prevent associated downstream risks, such as cardiovascular consequences in the future. Moreover, screening may minimise the present risk for sports-related injuries.
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